Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Theravance Inc (THRX)    
$11.78 0.00 (0.00%) as of 4:30 Fri 1/23


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 110,543,000 as of 6/30
Market Cap: 1.30(B)
Last Volume: 1,011,022 Avg Vol: 876,489
52 Week Range: $10.94 - $39.98
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Biotechnology

Member Indexes:

      

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  94
Guru Rank Value     : 9.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. Co. is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system / pain. Co.'s key programs include: RELVAR™ or BREO™ (fluticasone furoate/vilanterol), ANORO™ (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 832,456 1,005,107 1,665,106 5,170,076
Total Buy Value $2,147,483,647 $2,147,483,647 $2,147,483,647 $2,147,483,647
Total People Bought 1 1 1 1
Total Buy Transactions 1 2 4 8
Total Shares Sold 0 81,580 182,386 736,358
Total Sell Value $0 $1,825,039 $5,620,041 $24,544,724
Total People Sold 0 2 3 6
Total Sell Transactions 0 3 5 16
End Date 2014-11-02 2014-08-01 2014-01-31 2013-01-31

   
Records found: 459
  Page 1 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Witek Theodore L Jr Sr. VP, Corp Partnerships   •       –      –    2015-01-07 4 A $0.00 $0 D/D 71,429 71,429     -
   Desparbes Eric SVP and CFO   •       –      –    2015-01-07 4 A $0.00 $0 D/D 36,972 139,443     -
   Aguiar Michael W President & CEO   •       •      –    2015-01-07 4 A $0.00 $0 D/D 176,056 464,896     -
   Abercrombie George B Sr. VP, Corp. Partnerships   •       –      –    2015-01-07 4 A $0.00 $0 D/D 71,429 81,429     -
   Waltrip William H Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 3,250 103,314     -
   Tyree James L Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Pepe Paul Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Friedman Cathy Director   –       •      –    2014-12-22 4 A $0.00 $0 D/D 6,500 21,670     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2014-11-04 4 B $12,786,500.00 $2,147,483,647 I/I 832,456 31,581,179 1.5 -22%     
   Kearney Terrence C Director   –       •      –    2014-10-30 4 A $0.00 $0 D/D 23,133 23,133     -
   Desparbes Eric SVP and CFO   •       –      –    2014-10-16 4 A $0.00 $0 D/D 102,471 102,471     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 334,040     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 443,013     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 262,198     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2014-08-20 4 D $22.76 $74,220 D/D (3,261) 401,538     -
   Winningham Rick E Director   –       •      –    2014-08-15 4 D $0.00 $0 D/D (96,250) 825,391     -
   Aguiar Michael W President & CEO   •       •      –    2014-08-15 4 A $0.00 $0 D/D 43,905 288,840     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-13 4 S $22.50 $1,202,040 D/D (53,424) 265,459 50%     
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-08-13 4 OE $9.81 $926,264 D/D 74,441 318,883     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-12 4 S $22.30 $23,370 D/D (1,048) 446,274 50%     
   Glaxosmithkline Plc 10% Owner   –       –       •   2014-08-11 4 B $3,912,270.00 $2,147,483,647 I/I 172,651 30,748,723 1.5 -50%     
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-11 4 OE $14.53 $489,182 D/D 33,667 474,430     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2014-08-11 4 S $22.12 $599,629 D/D (27,108) 447,322 50%     
   Abercrombie George B Sr. VP, Corp. Partnerships   •       –      –    2014-06-19 4 A $0.00 $0 D/D 10,000 10,000     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2014-06-16 4 A $0.00 $0 D/D 28,365 244,935     -

  459 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed